论文部分内容阅读
目的探究在非小细胞肺癌的诊断中联合应用血清细胞角蛋白19片段、肿瘤相关糖链抗原、血管内皮生长因子检测(CYFRA21-1、CA125、VEGF)的价值。方法选取2014年1月-2015年1月医院收治肺小细胞癌患者80例为试验组,另选同期的肺良性病变患者80例为对照组。对2组患者的CYFRA21-1、CA125、VEGF三项指标予以检测并对结果进行比较。结果试验组各指标的检测结果均显著高于对照组,且均表达阳性,差异有统计学意义(P<0.05)。大细胞癌各指标检出率均较高,鳞癌CA125与VEGF检出率要显著低于大细胞癌,腺癌CYFRA21-1与VEGF的检出率要显著低于大细胞癌,鳞癌CA125检出率要显著低于腺癌,而腺癌CYFRA21-1的检出率要显著低于鳞癌,各指标比较差异有统计学意义(P<0.05)。结论 CYFRA21-1、CA125、VEGF检测具有较高的准确性,适用于非小细胞肺癌的诊断。
Objective To explore the value of combined application of serum cytokeratin 19, tumor-associated carbohydrate antigen, and vascular endothelial growth factor (CYFRA21-1, CA125, VEGF) in the diagnosis of non-small cell lung cancer. Methods From January 2014 to January 2015, 80 patients with small cell lung cancer admitted to the hospital were selected as the experimental group, and 80 patients with benign lung lesions in the same period were selected as the control group. The two groups of patients with CYFRA21-1, CA125, VEGF three indicators to be tested and the results were compared. Results The test results of each index in the experimental group were significantly higher than those in the control group, and all were positive, the difference was statistically significant (P <0.05). The detection rate of CA125 and VEGF in squamous cell carcinoma was significantly lower than that in large cell carcinoma. The detection rate of CYFRA21-1 and VEGF in adenocarcinoma was significantly lower than that in large cell carcinoma and squamous cell carcinoma CA125 The detection rate of CYFRA21-1 in adenocarcinoma was significantly lower than that in squamous cell carcinoma, the difference was statistically significant (P <0.05). Conclusion CYFRA21-1, CA125, VEGF detection with high accuracy, suitable for the diagnosis of non-small cell lung cancer.